Salvage surgery for advanced non–small cell lung cancer after response to gefitinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib

Published:2010-11 Issue:5 Volume:140 Page:e69-e71
ISSN:0022-5223
Container-title:The Journal of Thoracic and Cardiovascular Surgery
language:en
Short-container-title:The Journal of Thoracic and Cardiovascular Surgery

Author:

Hishida Tomoyuki,Nagai Kanji,Mitsudomi Tetsuya,Yokoi Kohei,Kondo Haruhiko,Horinouchi Hirohisa,Akiyama Hirohiko,Nagayasu Takeshi,Tsuboi Masahiro

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference5 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

2. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation;Takamochi;Lung Cancer,2007

3. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer;Kappers;J Clin Oncol,2008

4. Down-staging of EGFR mutation–positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases;Levchenko;Onkologie,2009

5. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer;Lara-Guerra;J Clin Oncol,2009

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rescue surgery in palliative indication as last therapeutic option for complicated advanced stage lung cancer;European Journal of Surgical Oncology;2023-12

2. Almonertinib as a neoadjuvant therapy for patients with a superior pulmonary sulcus tumor with activated EGFR mutation: A case report;Experimental and Therapeutic Medicine;2023-10-20

3. Survival impact of pathologic features after salvage lung resection following definitive chemoradiotherapy or systemic therapy for initially unresectable lung cancer;2023-10-17

4. Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma;Siberian journal of oncology;2023-02-21

5. Genomic Medicine and Lung Cancer Surgery;Haigan;2022-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3